ABUS vs LIN · P/E 5.4, rev $6.2M vs P/E 34, rev $33.99B
Arbutus Biopharma Corp (ABUS) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the ABUS and LIN stock pages for the full models.
Not investment advice.